Neurological ConditionsDeliVeriNNNCT07070310
DELirium, Incidence, preVEntion and pRogression During Acute Intensive Neurological -Neurosurgical Rehabilitation
An observational study of Neurological Conditions, run by Heart Centre Rotenburg at 1 site in Germany.
Trial summary
In this longitudinal cohort study the incidence of delirium is assessed for all patients being admitted to the acute intensive neurological-neurosurgical rehabilitation over 3 years. Delirium assessment will be performed daily from admission to discharge. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Neurological Conditions
- How many people
- 210 participants
- Where
- 1 siteGermany
- Study dates
- 15 Aug 2025to 15 Feb 2029
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patients in Neurosurgical rehabilitation
Who may be able to join
- Any patient admitted to acute neurological-seurosurgical rehabilitation
Who cannot join
- : patients with level of consciousness of coma or vegetative state
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Germany1 site
Herz-Kreislauf-Zentrum Klinikum Hersfeld Rotenburg GmbH, Klinik für Neurologie und Neurologische Rehabilitation
Rotenburg an der Fulda, 36199
Caroline Renner, Priv.-Doz. Dr. med., +49-6623-88-0, c.renner@hkz-rotenburg.de
About this study
Official title: DELirium, Incidence, preVEntion and pRogression During Acute Intensive Neurological -Neurosurgical Rehabilitation (Delirinzidenz Und Verlauf während Des Aufenthaltes in Der Neurologisch- Neurochirurgischen Frührehablilitation Der Phase B (NNFR))
In this longitudinal cohort study the incidence of delirium is assessed for all patients being admitted to the acute intensive neurological-neurosurgical rehabilitation over 3 years. Delirium assessment will be performed daily from admission to discharge. Patients will be divided into 3 groups, according to the presentation of delirium on admission, during the course or not any during the stay in acute rehabilitation and compared regarding the treatment and outcome.
- Conditions
- Neurological Conditions
What is being measured
The primary outcome is the main question the study is designed to answer.
incidence of delirium
Measured: 3 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted17 Jul 2025
- Study start15 Aug 2025 (estimated)
- Primary completion15 Aug 2028 (estimated)
- Study completion15 Feb 2029 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Neurological ConditionsStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 210 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Heart Centre Rotenburg
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Ralf Degenhardt, PhD, Heart Centre Rotenburg
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07070310
- Sponsor's protocol ID
- DeliVeriNN-01
- Acronym
- DeliVeriNN
- Status last verified
- Jul 2025
- First submitted
- 8 Jul 2025
- Last updated
- 22 Jul 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 22 Jul 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- DELirium, Incidence, preVEntion and pRogression During Acute Intensive Neurological -Neurosurgical Rehabilitation (Delirinzidenz Und Verlauf während Des Aufenthaltes in Der Neurologisch- Neurochirurgischen Frührehablilitation Der Phase B (NNFR))
- ClinicalTrials.gov ID
- NCT07070310
- Acronym / sponsor ID
- DeliVeriNN / DeliVeriNN-01
- Conditions
- Neurological Conditions
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 210 participants (estimated)
- Lead sponsor
- Heart Centre RotenburgUniversity, hospital or other
- Study start
- 15 Aug 2025 (estimated)
- Primary completion
- 15 Aug 2028 (estimated)
- Study completion
- 15 Feb 2029 (estimated)
- First posted
- 17 Jul 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
In this longitudinal cohort study the incidence of delirium is assessed for all patients being admitted to the acute intensive neurological-neurosurgical rehabilitation over 3 years. Delirium assessment will be performed daily from admission to discharge. Patients will be divided into 3 groups, according to the presentation of delirium on admission, during the course or not any during the stay in acute rehabilitation and compared regarding the treatment and outcome.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Patients in Neurosurgical rehabilitation
Key inclusion criteria (1 listed)
- Any patient admitted to acute neurological-seurosurgical rehabilitation
Key exclusion criteria (1 listed)
- : patients with level of consciousness of coma or vegetative state
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
incidence of delirium
Time frame: 3 years
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 22 Jul 2025.
- Individual participant dataSharing planned: No
Related trials for Neurological Conditions
Not yet recruiting
Effect of Stress Ball Use During Femoral Arterial Sheath Removal After Coronary Angiography
Femoral Arterial Sheath Removal, Stress Ball
Not yet recruiting
BrainGate2: Feasibility Study of an Intracortical Neural Interface System for Persons With Aphasia (BG-Aphasia-01)
Expressive Aphasia, Aphasia Following Cerebral Infarction
Recruiting
Empowered Relief® for Cancer Survivors With Chronic Pain
Chronic Pain Due to Cancer, Pain Catastrophizing
Enrolling by invitation
Online Exercise Program for Transplant Patients: A Pilot Study
Kidney Transplantation, Physical Function
Not yet recruitingPhase 1
Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)
Post-Acute COVID-19 Syndrome
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Neurological Conditions, run by Heart Centre Rotenburg at 1 site in Germany.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 22 Jul 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Germany. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Caroline Renner, Priv.-Doz. Dr. med (+49-6623-88-0, c.renner@hkz-rotenburg.de), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
incidence of delirium (time frame: 3 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 Jul 2025.